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Objectives: Few studies have assessed efﬁcacy and safety of prebiotics in infants at the time
of diversiﬁcation. We investigated the beneﬁcial effects of a follow-on milk formula
supplemented with short-chain fructo-oligosaccharides (scFOS) in healthy infants after 4
months of age.
Subjects/methods: 75 formula-fed healthy infants were included at the age of 4 months in a
randomized, controlled, double blind study and received either a placebo or scFOS
supplemented formula for six months. Faecal poliovirus sIgA after vaccination and
biﬁdobacteria concentration, height, weight and digestive tolerance were monitored.
Results: After 1 and 2 months of supplementation, no signiﬁcant difference was observed
between the groups for the evolution of poliovirus sIgA concentration compared to
baseline. A signiﬁcant increase in biﬁdobacteria count was observed after 1 month of
ScFOS supplementation, but this difference was no longer signiﬁcant after 2 months.
Breastfeeding history of infants was shown to have an impact on faecal biﬁdobacteria
evolution. Tolerance and growth parameters were similar in the 2 groups.
Conclusions: A follow-on milk formula supplemented with scFOS modulates intestinal
microbiota via an increase of faecal biﬁdobacteria concentration, while no effect on sIgA
concentrations could be demonstrated. scFOS addition elicited normal digestive tolerance
and normal growth suggesting it can be used safely at 5 g/L in infants after 4 months
of age.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
nd/4.0/).
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The development of the intestinal microbiota during the ﬁrst
months of life plays a crucial role towards a normal growth
and an optimal protection against infections. It is now well
established that the microbiota gut colonization in infants is
inﬂuenced by several parameters such as mode of delivery,
duration of gestation, antibiotic use, country of birth and type
of feeding (Fallani et al., 2010, 2011; Penders et al., 2006).
Breastfed neonates microbiota is mainly dominated by biﬁ-
dobacteria and lactic acid bacteria whereas in formula fed
babies the predominant organisms are enterococci (Balmer &
Wharton, 1989). Mode of feeding also modulates the immune
system (Holt, 1995), and it has been shown that the faecal
sIgA levels in formula-fed infants are lower than those
observed in breastfed infants (Koutras & Vigorita, 1989;
Kuitunen & Savilahti, 1995; Maruyama, Hida, Kohgo, &
Fukunaga, 2009). These data clearly indicate a positive impact
of breast milk components on the gut microbiota and
immune status of infants.
More than 130 different oligosaccharides have been iden-
tiﬁed in human milk and they are its 3rd most abundant
component. Several studies have suggested they may be able
to modulate the microbiota and immune system develop-
ment (Arslanoglu, Moro, & Boehm, 2007; Stepans et al., 2006).
Based on these results, several infant formulas supple-
mented with different types of oligosaccharides have been
marketed (Arslanoglu et al., 2007; Bruzzese et al., 2009;
Campeotto et al., 2011; Chen, Alarcon, Comer, & Tressler,
2002; Stam, van Stuijvenberg, Garssen, Knipping, & Sauer,
2011; Veereman-Wauters et al., 2011). Most of the studies
available have focused on a commercially available mixture
containing short chain galacto-oligosaccharides (scGOS) and
a high molecular weight fraction of inulin in a ratio 9:1
(Agostoni et al., 2010). This mixture has been shown to reduce
stool pH and stool viscosity (Kapiki et al., 2007; Mihatsch,
Hoegel, & Pohlandt, 2006), to modify gut microbiota in
preterm and term infants (Bruzzese et al., 2009; Knol et al.,
2005; Salvini et al., 2011) and to modulate the immune
response (Arslanoglu et al., 2007; Bakker-Zierikzee et al.,
2006; Bruzzese et al., 2009; Scholtens et al., 2008). Other
studies reported that infant formula supplemented withFig. 1 – Studyfructo-oligosaccharides (FOS) alone inﬂuenced the gut micro-
biota colonization (Brunser et al., 2006; Euler, Mitchell, Kline,
& Pickering, 2005; Paineau et al., 2014; Veereman-Wauters
et al., 2011).
However, while the vast majority of the studies point out
the beneﬁt of FOS in combination with other oligosaccharide
or alone for newborns or in early infancy, the impact of the
supplementation of follow-on formula on growth parameters,
tolerance, biﬁdogenic or immune effects in infants above 4
months of age is not known (Brunser et al., 2006; Salvini et al.,
2011; Stam et al., 2011). Vaccine-speciﬁc sIgA collected in
saliva or in faeces are considered as highly suitable markers
of immune response as they correlate with clinical endpoints
(Albers et al., 2013) and poliovirus is a typical vaccine of early
infancy with high coverage (Moturi et al., 2014) that stimu-
lates mucosal and intestinal immunity and induces detect-
able level of faecal sIgA (Pasetti, Simon, Sztein, & Levine,
2011). Moreover fructo-oligosaccharides (FOS) elicit immune
stimulation through the intestinal mucosa as shown in
animal models (Hosono et al., 2003; Nakamura et al., 2004)
and stimulate the growth of intestinal biﬁdobacteria (Paineau
et al., 2014) while biﬁdobacteria might have an implication for
improving response to poliovirus vaccine (Mullie et al., 2004).
In order to investigate if a short-chain FOS (scFOS) supple-
mentation in follow-on milk formula would achieve beneﬁ-
cial effects and would be well tolerated, we designed a
randomized, double-blind study against placebo in 4 months
old infants. We investigated the effect of 5 g/L scFOS on faecal
speciﬁc poliovirus secretory IgA (sIgA) level following vacci-
nation and on biﬁdobacteria faecal concentration after one
and two months of supplementation. The effect of scFOS on
digestive tolerance and growth parameters was also mon-
itored during the study in infants up to 10 months of age.2. Methods
2.1. Ethical considerations
The study was performed according to the Declaration of
Helsinki II Principles and was approved by the Ethics Commit-
tee of the Fundació Unió Catalana D'Hospitals on 12th January
2009. All parents or caregivers of the participating infantstimeline.
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trial was registered at www.clinicaltrials.gov (NCT00948051).
2.2. Study design
The study was a placebo-controlled, double-blind rando-
mized prospective design. scFOS or placebo formula was
administered throughout the study which was divided in 4
visits: selection/randomization visit (V1-Baseline) [2nd DTP
poliovirus injection visit], 1 month treatment visit (V2), 2
months treatment visit (V3) [3rd DTP poliovirus injection
visit], and 6 months treatment visit (V4). Three interim phone
contacts or optional sites visits (one each month) were
planned between V3 and V4, for collection of information
regarding the infant's health status. Study timeline is
described in Fig. 1.
2.3. Outcomes measures
The primary endpoint of the study was to evaluate the
evolution of the immune response to poliovirus vaccination,
via the measurement of the speciﬁc poliovirus sIgA faecal
concentration after one and two months of feeding with
scFOS or placebo supplemented follow-on milk formula.
Faecal concentration of biﬁdobacteria and the frequency
and incidence of infectious events were also evaluated as
secondary efﬁcacy criteria. Finally, weight, height, digestive
tolerance (i.e., constipation, crying, soft stool, vomiting and
regurgitation), adverse events (AEs) and serious adverse
events (SAEs) were evaluated after 6 months of scFOS or
placebo supplemented follow-on milk formula intake.
2.4. Study participants
All infants were included from 17 Spanish paediatric out-
patient units in the Barcelona province. The Spanish polio
vaccination programme consists of 4 injections of inactivated
poliovirus with the three ﬁrst doses administrated at 2, 4 and
6 months of age. In order to recruit the target population, a
pre-selection period was set-up at the ﬁrst tetanus poliovirus
vaccination injection prior to the 6-month study. During this
period, the Investigator identiﬁed potentially randomizable
subjects. When the infant met all entrance criteria, the
Investigator orally explained to the accompanying adult theTable 1 – Nutritional composition of the follow-on formulae.
Composition Control formula
Per 100 g Per 100 mL
Energy (kcal) 488.0 68.3
Proteins (g) 14.5 2.0
Carbohydrates (g) 58.0 8.1
scFOSa – –
Fat 22.0 3.1
List of ingredients: Skimmed milk, maltodextrin, vegetal oil (palm, sunﬂo
Cl, Ca, P, Mg, Fe, Zn, Cu, I, Se) emulsifying agent, soya lecithin, vitamins
biotine, D, B12), inositol, antioxidants (tocopherol blend, ascorbic palmit
a Caloric value of pure scFOS is 2 kcal/gobjectives, the schedule, the expected beneﬁts and the con-
straints of the trial and dispensed the Information Leaﬂet and
the Informed Consent Form (ICF). The signed ICFs have been
collected during the second poliovirus vaccination injection,
which was the selection/randomization visit. Finally, infants
included in the study were aged 4 months (72 weeks) at
randomization, not breastfed or who had stopped breastfeed-
ing for at least 1 month prior to inclusion and who were
available for 8 months following randomization. Infants
suffering from a chronic or severe disease susceptible to
interfere with one of the evaluation criteria or suffering a
gastro-intestinal disease (short bowel, cystic ﬁbrosis, malab-
sorption, constipation, cow milk allergy), infants who had
taken antibiotics during the 2 months preceding randomiza-
tion, infants fed with FOS supplemented follow-on milk
formula or regularly receiving yogurt or fermented dairy
product before, or had a concomitant use of laxative or
anti-secretory drugs that could modify intestinal ﬂora and
infant whose vaccination programme deviated from the one
requested by the protocol, were excluded.
2.5. Study product description
Infants meeting all eligibility criteria were randomized (1:1
ratio) either in the scFOS group (follow-on milk formula
supplemented with scFOS – Actilights 950P, Beghin-Meiji,
Marckolsheim, France – at 5 g/L – 3.5% in replacement of
maltodextrins in the powder) or in the control group (follow-
on milk formula without scFOS supplementation) (Table 1).
2.6. Blinding and randomization
Both follow-on milk formulas (with or without FOS) have
been supplied by Laboratorios Ordesa in identical packages
labelled with randomization codes. The study remained in
blinded conditions for all participants, investigators, moni-
tors, data managers and statisticians. To ensure equal pro-
duct repartition throughout the study, a computed, blocks of
four, randomization list stratiﬁed by centre was generated by
an automated random number system by the coordination
Contract Research Organization (not involved in recruiting
participants and in assigning treatment). Each investigator
had his own randomization list on site providing him rando-
mization codes. The randomization codes were assigned toscFOS formula
at 14% Per 100 g Per 100 mL at 14%
481.0 67.3
14.5 2.0
54.5 7.6
3.3 0.5
22.0 3.1
wer, high oleic palm), serum proteins, lactose, minerals salts (Na, K,
(C, E, nicotinamide, calcium pantotenate, B6, B2, B1, A, K, folic acid,
ate)
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were included in the centre.
2.7. Sample collection and preparation
The day before each visit (at ages of 4–6 months), parents were
asked to collect stool samples from the diaper with a spatula.
These were placed in white opaque plastic pot, put in an
Anaerocults A bag (Merck Chemicals, Darmstadt, Germany)
and stored in refrigerator until the visit day on which faecal
homogenates were frozen at 20 1C by the Investigator. Homo-
genates were then thawed on ice bath and suspensions
prepared by adding 1 g faeces to 9ml of phosphate-buffered
saline (PBS) then homogenized for 10min using a stomacher.
The homogenates were stored at 80 1C until further proces-
sing to determine sIgA and Biﬁdobacteria levels.
2.8. Faecal poliovirus-speciﬁc sIgA determination
For the determination of poliovirus-speciﬁc sIgA concentration,
an enzyme-linked immunosorbent assay (ELISA) was per-
formed as described by Ostrom et al. (2002). Brieﬂy, 10% (w/v)
faecal homogenates were prepared according to standard
procedures. Coated ELISA plates were incubated for 2 h at
room temperature with supernatants of the faecal homoge-
nates. Puriﬁed human IgA isolated from colostrum (I-1010;
Sigma) was used as positive standard. Plates were then
incubated with biotin/conjugated mouse anti-human IgA1/2
monoclonal antibody (clone G20-359; BD Biosciences Palo
Alto, CA, USA) for 1 h and then with streptavidin-conju-
gated horseradish peroxidase (CLB, M2051). The wells were
ﬁnally treated with a tetramethylbenzidine (TMB) substrate
solution. Enzymatic colour development was stopped by
adding H2SO4 and absorbance values were measured at
450 nm. Concentrations of sIgA were determined by using a
standard curve.
2.9. Microbiological analysis
Biﬁdobacterial genera identiﬁcation was performed by PCR
methods according to Kok et al. (1996). Species identiﬁcation
was realized using a multiplex PCR targeting the 16S–23S
rRNA gene intergenic spacer as reported by Mullie Odou,
Singer, Romond, and Izard (2003).
2.10. Anthropometry
The infants' birth weights, lengths and head circumferences
were obtained from their hospital records. Then, the weight
and height were measured at each visit. Values were com-
pared to WHO child growth standards (Bloem, 2007).
2.11. Adverse events and digestive tolerance
The parents or legal guardian were asked to report all
information regarding infectious events and symptoms (fever
episodes, sore throat, skin rash, etc.) and antibiotics intake in
the study booklet between each visit. Also, they were asked to
report all information regarding digestive tolerance of the
product, especially the incidence of the following digestivesymptoms: abdominal pain evaluated by counting the num-
ber of days of constipation, crying, soft stool, nausea, vomit-
ing and regurgitation. All AEs, regardless of their seriousness
or relationship to study product, were recorded on the
corresponding page of the Case Report Form (CRF). The AEs
were coded using the latest version of the Medical Dictionary
for Regulatory Activities (MedDRA). All AEs were listed and
summarized by product group using the number and percen-
tage of infants in the tolerance population.
2.12. Product compliance assessment
In order to verify products intake and to evaluate the daily
intake of scFOS during the study, parents completed during
the week preceding each visit a 7-day diet diary in which
were reported the exact quantity (in mL) of follow-on formula
drunk by the infant.
2.13. Statistical analysis
Based on the previously studied effects of a prebiotic formula
on faecal levels of poliovirus-speciﬁc sIgA (Paineau et al.,
2014), a sample size of 30 individuals in each group (taken
into account 10% post-randomization losses) was needed to
detect a difference of 6 mg of antipoliovirus sIgA per mg of wet
faeces between both groups considering a standard devia-
tions of 11 and 4 mg/mg (a¼5%, power 80%, a two-sided two-
sample t-test). As the estimated pre-randomization loss rate
for this population was 50%, approximately 120 infants were
planned to be pre-selected during the 3-month recruitment
period, and approximately 60 were planned to be randomized
in the two parallel arms of the trial, with a 1:1 ratio.
The statistical populations for the analysis were deﬁned as
follows:– Efﬁcacy population: All randomized infants who fulﬁlled
all selection criteria, consumed the study product at least
once and were not treated with antibiotics between V1
and V2 for the one month treatment visit and between V2
and V3 for the two months treatment visit.– Tolerance population: All randomized infants who had
ingested least once the study product between V1 and V3.
Data from all infants who met the inclusion and exclusion
criteria were used for statistical analysis.
Following the analysis of the results of the study, a post-
hoc analysis was performed in order to investigate if the
effect of the scFOS could be related to the breastfeeding
history. For each efﬁcacy population (placebo and treatment)
two subgroups were created (previously breastfed and never
breastfed) and analysed. Both scFOS and control groups
showed a similar distribution between previously breastfed
and never breastfed infants.
Statistical analyses were performed using the Statistical
Analysis System (SAS) software, version 9.2. The signiﬁcance
level for all statistic tests was considered 0.05. Data from all
clinical assessments, including baseline characteristics of
the infants, were summarized by visit using descriptive
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poliovirus-speciﬁc sIgA in stools after 1 month and 2 months
of supplementation. Normality was assessed using the Sha-
piro–Wilk test. sIgA concentrations were compared using a
two-sample t-test or a Mann–Whitney test, when appropri-
ate. All analyses were two-sided.
For the secondary endpoints (tolerance and biﬁdobacteria)
comparisons between groups were performed using a Chi
square test or a Fisher's exact test as appropriate for catego-
rical data (frequency of infectious diseases and digestive
tolerance of the product), whereas continuous variables (biﬁ-
dobacteria counts) were compared using a two-sample t-test
or a Mann–Whitney test, depending on data distribution.Fig. 2 – Weight and height evolution of infants after 6
months of intake of the control or scFOS follow-on formula.3. Results
3.1. Demographic and anthropometric parameters
At enrolment the infants in the two groups had similar
demographic and birth characteristics (Table 2). The evolu-
tion of weight and height during the study remained within
normal range and no signiﬁcant difference was observed
between the groups (Fig. 2).
3.2. Study population
A total of 75 infants were enroled in this study, of which 38
and 37 exclusively received a formula with scFOS or a control
formula, respectively. The ﬂowchart of enroled infants and
the number of infant who provided individual data for the
measurement of the different clinical outcomes is presented
in Fig. 3 while the distribution of previously breastfed and
never breastfed infants for each efﬁcacy population is shown
in Table 3. There were no differences between the two groups
in the total numbers of withdrawals or in their reasons for
withdrawing from the study.
3.3. Immunoglobulin levels evolution
At enrolment, the sIgA mean concentration in the control
group was signiﬁcantly higher than in the scFOS group
(Table 4). The control group had sIgA mean concentration of
28.5975.02 mg/mg, while the scFOS group had a mean con-
centration of 14.5773.13 mg/mg (p¼0.0188). It is also note-
worthy that the two populations did not differ in other
parameters including demography, nutritional status and
vaccinal status. Besides, a high standard error on sIgATable 2 – Demographic characteristics of the efﬁcacy populatio
N
Gender (M/F)
Age (weeks, 7S.E.)
Birth weight (kg, 7S.E.)
Birth height (cm, 7S.E.)
Gestational age (weeks, 7S.E.)
Mode of delivery(Vaginal/caesarean section)concentrations was observed throughout the study period.
After one and two months of supplementation (Table 4), the
mean change in sIgA concentration compared to baseline
values was not signiﬁcantly different between the scFOS and
control groups (Table 4).
The modiﬁcation of sIgA concentration after 1 and 2
months of supplementation for previously breastfed and
never breastfed infants was compared in a post-hoc analysis.
However, no signiﬁcant difference between the scFOS group
and the control group was observed. In previously breastfed
infants, a trend for an increase in the scFOS group and in the
control group a decrease of sIgA was noticed in infants after
one month (4.6374.63 vs 12.3579.31 mg/mg; p¼0.13) and 2
months (0.9079.49 vs 14.66710.31 mg/mg; p¼0.28) of sup-
plementation (Table 4).n (7S.E.).
Control group scFOS group
31 33
13/18 17/16
17.8070.12 17.7670.21
3.1670.08 3.1670.07
48.8670.36 48.8570.31
38.9770.23 38.9270.22
23/8 23/10
Fig. 3 – Study ﬂow diagram.
Table 3 – Feeding History of analysed populations.
Breastfed Non breastfed
ONE MONTH FOLLOW-UP
Control group n¼12 n¼19
FOS group n¼11 n¼22
TWO MONTHS FOLLOW-UP
Control group n¼12 n¼20
FOS group n¼12 n¼21
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No difference on biﬁdobacteria count was observed at base-
line between the control and the scFOS groups (Table 5). For
the overall population, a signiﬁcant increase of biﬁdobacteria
was observed after one month of supplementation in the
scFOS group compared to baseline (p¼0.03). The effect was nolonger signiﬁcant after two months of supplementation
(p¼0.25) (Table 5). As for the immunoglobulin parameter, a
post-hoc analysis was performed in order to evaluate if the
feeding history (previously breastfed vs never breastfed) may
be a factor of differentiation in the biﬁdobacteria count
evolution (Table 5). In the subgroup of infants who were
never breastfed, the change in biﬁdobacteria concentration
after one month of supplementation was higher in infants
who received scFOS milk formula, compared with infants
receiving milk formula without scFOS (p¼0.014). When
changes from visit 1 (baseline) to visit 3 were assessed the
effect observed in never breastfed infants with the scFOS was
no longer signiﬁcant (p¼0.45). In previously breastfed infants,
there were no signiﬁcant differences between infants receiv-
ing milk formula with and without scFOS.3.5. Tolerance
During the study, no signiﬁcant differences were found in the
number of infants with concomitant treatments between
both study groups (p¼0.12). Overall, 81% of infants experi-
enced at least one AE, with no signiﬁcant difference in the
number of AEs between groups. The most prevalent AEs in all
infants were nasopharyngitis (28%), bronchitis (12%), and
gastroenteritis (9%). No difference was observed between
groups for diarrhoea and gastroenteritis. When focusing on
adverse events of infectious origin, as deﬁned post-study by a
medical expert, 81% of infants suffered at least one infectious
AE but the prevalence of infections was not signiﬁcantly
different between groups (p¼0.08). During the study, 6 dif-
ferent infants suffered from serious adverse events; one
infant in the control group had bronchitis and pharyngitis,
for a mean duration of 3 days and 5 in the scFOS group
including bronchitis, bronchiolitis, ear infection, gastroenter-
itis, inguinal hernia repair, pyelonephritis, and regurgitation,
for a mean duration of 3 days as well over a period of about
180 days. None of the serious adverse events was related to
the study product.3.6. Digestive tolerance
Digestive tolerance was evaluated during the 6 month-study
for infants who received at least one feeding of follow-on
milk per day, (equivalent to at least 2.5 g/day) (Table 6). There
was no difference between the 2 groups in terms of preva-
lence of digestive symptoms except for the number of days
with vomiting that was lower (p¼0.05) and the number
of days with soft stools that was higher (p¼0.03) in the
scFOS group.4. Discussion
This study is among the ﬁrst conducted to evaluate the
beneﬁts of a follow-on milk formula supplemented with
scFOS alone in infants above 4 months of age on speciﬁc
faecal sIgA secretion after a poliovirus vaccination and on
biﬁdobacteria population. Since there is a lack of studies in
this age group, digestive tolerance and growth were also
Table 4 – Faecal SIgA poliovirus (lg/mg) baseline data and evolution after 1 and 2 months of treatment – efﬁcacy
population.
Baseline (V1) values 1 month follow-up (V2) change vs V1 2 months follow-up (V3) change vs V1
Control
(7S.E.)
scFOS (7S.E.) p Value Control
(7S.E.)
scFOS
(7S.E.)
p Value Control
(7S.E.)
scFOS
(7S.E.)
p Value
Overall
28.5975.02 14.5773.13 0.02 7.1275.04 2.4673.49 0.12 6.3175.61 2.9775.55 0.24
Previously breastfed
32.1779.18 19.67710.8 0.38 12.3579.31 4.6374.63 0.13 14.66710.31 0.9079.49 0.28
Never breastfed
28.0475.88 17.6974.04 0.15 3.8175.84 1.3874.75 0.49 1.3176.45 4.1577.00 0.57
Table 5 – Faecal biﬁdobacteria (logCFU/g stool) baseline data and evolution after 1 and 2 months of treatment – efﬁcacy
population.
Baseline (V1) values 1 month follow-up (V2) change vs V1 2 months follow-up (V3) change vs V1
Control
(7S.E.)
scFOS
(7S.E.)
p Value Control
(7S.E.)
scFOS
(7S.E.)
p Value Control
(7S.E.)
scFOS
(7S.E.)
p Value
Overall
4.4770.22 3.9670.30 0.08 0.0770.15 0.7470.33 0.03 0.0670.33 0.49 70.34 0.25
Previously breastfed
4.8370.06 4.3170.43 0,26 0.0670.11 0.1870.62 0.85 0.4470.37 0.2170.59 0.36
Never breastfed
4.2870.34 3.5070.46 0,18 0.1670.69 1.0270.38 0.01 0.1670.48 0.6470.36 0.45
Table 6 – Digestive tolerance parameters after 6 months follow-up.
Digestive tolerance parameters Control group scFOS group p-Value
Regurgitation % of prevalence 50.0 54.1 0.73
Mean number of days (7S.E.) 30.075.8 27.775.0 0.79
Vomiting % of prevalence 47.4 54.1 0.56
Mean number of days (7S.E.) 7.771.3 4.170.7 0.05
Soft stools % of prevalence 60.5 73.0 0.25
Mean number of days (7S.E.) 5.870.9 13.872.9 0.03
Constipation % of prevalence 52.6 48.6 0.73
Mean number of days (7S.E.) 18.274.7 9.872.4 0.23
Crying % of prevalence 39.5 40.5 0.92
Mean number of days (7S.E.) 20.776.0 18.6775.2 0.85
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of 10 months.
We were not able to show any signiﬁcant increase of post
vaccine sIgA response against polio virus. This is likely to be
related to the high variability of the sIgA response amongst
individuals. In this respect our study was underpowered on
this criterion. Indeed, to reach a statistical signiﬁcance, the
sIgA evolution observed between the control and scFOS would
have needed a sample size of around 100 subjects. Several
explanations can be raised towards the high variability
observed. The absence of negative control for the sIgA criterionis a major limitation of the study. False positive samples or
biased readings are likely to have occurred through the
presence of factor other than IgA (enzymes) splitting peroxide
and thus causing colour development. Furthermore other
authors have also observed high variability on sIgA values in
different populations. Kato et al. reported a high variability in
baseline sIgA values in healthy adults but did not raise any
possible explanation to this observation (Kato et al., 2014).
Bakker et al. observed such high variability in infants and
raised the hypothesis that past infections history may inﬂu-
ence sIgA values in infants (Bakker-Zierikzee et al., 2006). Data
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after the beginning of treatment but past infections history of
infants was not recorded at baseline and not taken into
account when interpreting the results. Another potential
explanation to the variability may be related to the feeding
history of infants prior to the vaccination or during the study
(time and modalities of diversiﬁcation).
To date, few trials have been performed to investigate the
effect of prebiotic carbohydrates on the vaccine-speciﬁc anti-
body responses especially in infants older than 4 months and
it remains difﬁcult to establish a scientiﬁc consensus on their
beneﬁcial effect on vaccination (Bakker-Zierikzee et al., 2006;
Koutras & Vigorita, 1989; Kuitunen & Savilahti, 1995;
Maruyama et al., 2009). Indeed, most of the available evidence
addresses the effect on non speciﬁc sIgA response or focuses
on infants prior to food diversiﬁcation. In a prospective,
randomized double-blind study, never breastfed infants fed
a prebiotic formula (mixture Galacto-oligosaccharides (GOS)/
inulin) showed a trend towards higher faecal secretory sIgA
levels compared with the standard formula-fed infants,
reaching statistical signiﬁcance only at the age of 16 weeks
(Bakker-Zierikzee et al., 2006). Several reports also showed
that faecal sIgA levels in formula-fed infants are lower than
those in breastfed infants, and that faecal sIgA level in
breastfed infants and in formula-fed infants usually reached
its peak around 2 months of age and then decreased before
reaching a similar level in all groups after 6 months of age
(Koutras & Vigorita, 1989; Kuitunen & Savilahti, 1995;
Maruyama et al., 2009). Finally, it was also reported that a
mixture of three prebiotic carbohydrates, i.e. scGOS/inulin
ratio 9:1 and a pectin-derived acidic oligosaccharide, was not
able to increase the vaccination speciﬁc antibody levels in
children up to the age of 12 months. In this study the vaccine
speciﬁc antibody levels in infants fed prebiotics or a control
diet were similar during the ﬁrst year of life and the authors
hypothesized that prebiotic mixture is more likely to promote
Th1 and Treg dependent immune responses than vaccine-
speciﬁc serum antibody responses, and therefore might be
more active on allergic issues in infants (Stam et al., 2011).
Our data reported for the ﬁrst time a biﬁdogenic effect of
scFOS alone at 5 g/L after one month of supplementation in
infants older than 4 months. This is complementary to the
published data showing that oligofructose obtained from
hydrolysis of chicory inulin alone or in a mix of oligofruc-
tose/inulin can modulate gut microbiota after one month of
supplementation in newborn infants (Paineau et al., 2014;
Veereman-Wauters et al., 2011) and conﬁrms results from
another intervention trial with scFOS added in infant for-
mulae at 4 g/L from birth to 4 months of age. We have also
shown after post-hoc analysis that previous breastfeeding
history inﬂuences this biﬁdogenic effect, since the beneﬁt of
scFOS after the age of 4 months was only observed in the
never breastfed infants. These results complement those
previously reported on a scGOS/inulin or oligofructose/inulin
mix at 8 g/L (Knol et al., 2005; Veereman-Wauters et al., 2011).
The study did not show a similar long-lasting effect on the
faecal concentration of biﬁdobacteria as previously reported
on infants exclusively fed with a formula supplemented with
scGOS/inulin from the ﬁrst day of life and during 12 months
(Salvini et al., 2011) as the stimulation of faecal biﬁdobacteriawas not seen any more after 2 months. While this might be
explained by a higher supplementation dose in the study of
Salvini et al. (8 g/L instead of 5 g/L in our study), our results
also raise the issues of the impact of breastfeeding history
prior to food diversiﬁcation on the infant gut ﬂora evolution.
Several observational trials have highlighted the impact of
breastfeeding history on biﬁdobacteria count and diversity
and more globally on microbial species found in infants' gut
(Fallani et al., 2011; Roger, Costabile, Holland, Hoyles, &
McCartney, 2010). Levels of biﬁdobacteria found in faecal
samples of infants in our study are lower than results
reported elsewhere. These values should be regarded with
respect to the location of the study and the faecal samples
analysis process and methodology. Spanish infants were
shown to display much lower faecal biﬁdobacteria counts
when compared to infants from other European countries
(Fallani et al., 2010) potentially explaining the low levels
observed here. Moreover in our study parents were asked to
collect stool samples in diapers the day before the visit and to
store them in the refrigerator while bacterial diversity and
total number of bacteria is inﬂuenced rapidly at room
temperature and 4 1C (Ott et al., 2004). All PCR analyses were
performed at the end of the trial while storage time is a key
factor in the conservation of bacterial DNA (Rochet, Rigottier-
Gois, Rabot, & Dore, 2004). These points could be overcome in
future studies by improving the time between stools collec-
tion and analysis. Endly more accurate primers could be used
for faecal samples analysis (Sim et al., 2012).
After 6 months of supplementation, the strict follow-up of
adverse events and digestive tolerance criteria have demon-
strated the good tolerance of scFOS follow-on milk, as no
difference was observed between groups for diarrhoea, gas-
troenteritis, prevalence of infections, regurgitation, constipa-
tion and crying while these conditions are common at this
lifestage. It should also be noticed that infants consuming the
scFOS supplemented formula have experienced an improve-
ment in vomiting prevalence and in stool consistency. Ana-
lysis of serious adverse events was undertaken to determine
their possible link with the study product. Causal link
between scFOS ingestion and gastro-enteritis, inguinal hernia
repair and pyelonephritis was completely excluded. Other
SAEs experienced in the scFOS but not in the control group
(bronchitis, bronchiolitis or ear infections) were also analysed
for their possible causality with the study product. Events of
such type have been suspected to be related to regurgitation
(referring to the passage of gastric contents into the oeso-
phagus oropharynx) or GERD (Gastro-Esophageal Reﬂux Dis-
ease, i.e when regurgitation is the cause of troublesome
symptoms and/or complications). However despite studies
suggesting a possible association, current clinical evidence
does not support this relationship (Sherman et al., 2009) and
our data as well as those from other trials in scFOS supple-
mented formulae (Moro et al., 2002; Paineau et al., 2014) did
not indicate any impact of scFOS on the incidence of regur-
gitation, thus excluding this hypothesis. Finally the duration
of the SAEs observed in the scFOS group (3 days or less out of
a period of 180 days) more likely suggests viral infections that
cannot be linked to the addition of the ﬁbre in the formula.
Moreover, the evolution of weight and height during the
study was similar between the groups. Our data complement
B i o a c t i v e C a r b o h y d r a t e s a n d D i e t a r y F i b r e 5 ( 2 0 1 5 ) 1 6 9 – 1 7 8 177previous results showing no negative impact on growth of
FOS supplementation at dose from 3 to 8 g/L in younger
infants after 4 and 5 weeks of supplementation (Euler et al.,
2005; Veereman-Wauters et al., 2011).
4.1. Conclusions
The results of this study show that a follow-on milk formula
supplemented with 5 g/L scFOS is safe and well tolerated
leading to normal growth in infants after the age of 4 months
and promotes faecal biﬁdobacteria levels after one month in
never breastfed infants. Maintenance of this effect at longer
term would require further investigations.Acknowledgements
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